TORNTPHARM₹4,925.00

Torrent Pharmaceuticals Ltd.

· Pharma & Health
AnnualQuarterly₹ CrorePeersSUNPHARMAJBCHEPHARMMANKINDZYDUSLIFEDIVISLABMAXHEALTHDRREDDYCIPLAMcap ₹1.67L Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q2 FY24
30/09/2023
Q3 FY24
31/12/2023
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations2,660.02,732.02,745.02,859.02,889.02,809.02,959.03,178.03,302.03,303.04,197.04,921.0
Other Income26.0-33.031.024.0-16.033.0-18.0-37.0-27.0-13.0-17.0-12.0
Total Income2,686.02,699.02,776.02,883.02,873.02,842.02,941.03,141.03,275.03,290.04,180.04,909.0
Expenses
+ Cost of Materials Consumed433.0379.0410.0411.0337.0370.0402.0396.0382.0414.0566.0609.0
+ Purchases of Stock-in-Trade292.0327.0315.0313.0382.0420.0416.0338.0382.0422.0477.0531.0
+ Changes in Inventories-65.0-9.0-46.0-30.0-41.0-117.0-87.040.036.0-37.0-28.023.0
+ Employee Benefit Expense503.0496.0486.0550.0543.0549.0561.0605.0627.0651.0788.0893.0
+ Finance Costs91.080.080.075.064.057.056.056.048.045.0236.0305.0
+ Depreciation & Amortisation201.0213.0203.0197.0198.0199.0201.0201.0204.0206.0508.0593.0
+ Other Expenses672.0670.0697.0711.0729.0673.0703.0767.0792.0765.01,038.01,201.0
Total Expenses2,127.02,156.02,145.02,227.02,212.02,151.02,252.02,403.02,471.02,466.03,585.04,155.0
EBITDA825.0869.0883.0904.0939.0914.0964.01,032.01,083.01,088.01,356.01,664.0
EBIT624.0656.0680.0707.0741.0715.0763.0831.0879.0882.0848.01,071.0
Profit
PBT before Exceptional Items559.0543.0631.0656.0661.0691.0689.0738.0804.0824.0595.0754.0
+ Exceptional Items0.088.00.00.00.00.0-24.00.0-13.0-10.0-66.0-21.0
Pretax Income559.0631.0631.0656.0661.0691.0665.0738.0791.0814.0529.0733.0
+ Current Tax120.0106.0142.0126.0156.0153.0184.0201.0233.0244.0166.0254.0
+ Deferred Tax53.082.040.073.052.035.0-17.0-11.0-33.0-65.0-1.0-87.0
Tax Expense173.0188.0182.0199.0208.0188.0167.0190.0200.0179.0165.0167.0
Net Income386.0443.0449.0457.0453.0503.0498.0548.0591.0635.0364.0566.0
+ Net Income — Continuing Ops386.0443.0449.0457.0453.0503.0498.0548.0591.0635.0364.0566.0
+ Other Comprehensive Income-23.0-1.01.0-34.0-25.0-70.036.0-2.0-76.0-16.0-86.079.0
Total Comprehensive Income363.0442.0450.0423.0428.0433.0534.0546.0515.0619.0278.0645.0
Net Income to Common363.0442.0449.0457.0——498.0548.0591.0635.0389.0566.0
Minority Interest0.00.00.00.0——0.00.00.00.0-25.00.0
Per Share
Basic EPS11.3913.1013.2713.5113.3714.8814.7116.1917.4518.7711.5114.87
Diluted EPS11.3913.1013.2713.5113.3714.8814.7116.1917.4518.7711.5114.87
Other Comprehensive Income — detail
+ Other Comprehensive Income——————36.0-2.0-76.0-16.0-86.079.0
+ Items NOT to be Reclassified to P&L-3.0-6.04.0-5.0-7.0-7.0-9.0-9.0-3.0-9.021.0-17.0
+ Tax on Items NOT to be Reclassified——————1.0-2.0-1.0-1.04.0-4.0
+ Tax on Items NOT to be Reclassified — alt tag-1.0-2.02.0-2.0-2.0-3.0——————
+ Items to be Reclassified to P&L-22.0-2.04.0-29.0-33.0-68.052.0-2.0-92.0-7.0-127.0119.0
+ Tax on Items to be Reclassified——————6.0-7.0-18.01.0-24.027.0
+ Tax on Items to be Reclassified — alt tag-1.0-5.05.02.0-13.0-2.0——————
Comprehensive Income — Owners of Parent363.0442.0450.0423.0428.0433.0534.0546.0515.0619.0302.0645.0
Comprehensive Income — Non-controlling Interests0.00.00.00.00.00.00.00.00.00.0-24.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations11.3913.1013.2713.5113.3714.8814.7116.1917.4518.7711.5114.87
Diluted EPS — Continuing Operations11.3913.1013.2713.5113.3714.8814.7116.1917.4518.7711.5114.87
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit2,000.02,035.02,066.02,165.02,211.02,136.02,228.02,404.02,502.02,504.03,182.03,758.0
Gross Margin %75.1974.4975.2675.7376.5376.0475.3075.6575.7775.8175.8276.37
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)559.0543.0631.0656.0661.0691.0689.0738.0804.0824.0595.0754.0
− Exceptional Items (reconciliation)0.088.00.00.00.00.0-24.00.0-13.0-10.0-66.0-21.0
Net Income Adj (tax-effected)386.0381.2449.0457.0453.0503.0516.0548.0600.7642.8409.4582.2
EPS Adj11.3911.2713.2713.5113.3714.8815.2416.1917.7419.0012.9515.30
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value5.005.005.005.005.005.005.005.005.005.005.005.00
Filed Debt Equity0.01—————0.00—————
Filed Dscr0.04—————0.05—————
Filed Iscr0.08—————0.14—————
Paid Up Equity Capital169.2169.2169.2169.2169.2169.2169.2169.2169.2169.2169.2169.2
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.